C17 is measuring academic clinical trial accruals in Canada as part of 3CTN. If your study is eligible and not on the portfolio, please contact C17.

3CTN is an initiative to increase participation in academic oncology clinical trials in Canada (www.3ctn.ca).  As part of this project, C17 is tracking enrollment on pediatric clinical trials that are eligible for the 3CTN portfolio, and we would like to ensure that we have included all eligible studies.  We are aware of studies that we sponsor (e.g., COG, TACL),  but for other studies we rely on information from you, the researchers.

Are you aware of a study pediatric oncology study that meets the criteria below, please contact Leah in the C17 Council office (leah.young2@ahs.ca).

  • intervention study
  • open at more than one site in Canada (second site does not need to be a pediatric oncology/hematology centre)
  • not sponsored by industry

Note that a CTA is not required for eligibility, but a study would have to be listed on clinicaltrials.gov to go on the 3CTN portfolio.